Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
The company’s EBITDA margin remained resilient above 20%
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG clinicians contributing to one of the largest bodies of oncology research from India
Subscribe To Our Newsletter & Stay Updated